|Articles|April 30, 2004

Enbrel (etanercept) approved for the treatment of adult patients with chronic moderate to severe plaque psoriasis

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--April 30 ? Amgen Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced Friday that Enbrel (etanercept) has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME